<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">detinf</journal-id><journal-title-group><journal-title xml:lang="ru">ДЕТСКИЕ ИНФЕКЦИИ</journal-title><trans-title-group xml:lang="en"><trans-title>CHILDREN INFECTIONS</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-8107</issn><issn pub-type="epub">2618-8139</issn><publisher><publisher-name>Association of Pediatricians and Infection Disease doctors</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22627/2072-8107-2015-14-3-17-26</article-id><article-id custom-type="elpub" pub-id-type="custom">detinf-165</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Клинико-лабораторные характеристики, лечение и прогноз синдрома Гийена-Барре у детей</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and Laboratory Features, Treatment and Prognosis in Children with Guillian-Barre Syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>СУПОНЕВА</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Suponeva</surname><given-names>N. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>ШАКАРЯН</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Shakaryan</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач Клинического отдела Института полиомиелита, ИКБ № 1, корпус 1, 5 отделение; 125367, Москва, Волоколамское шоссе, д. 63; (499) 193-53-89</p></bio><bio xml:lang="en"><p>Clinical department Institute of Poliomyelitis, 125367, Moscow, Russia, Volokolamskoe sh. 63, (499)139-53-89</p></bio><email xlink:type="simple">1935389@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>РАХТЕЕНКО</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakhteenko</surname><given-names>A. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>ПИРАДОВ</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Piradov</surname><given-names>M. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>МИТРОФАНОВА</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mitrofanova</surname><given-names>I. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>ПРЫТКОВА</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Prytkova</surname><given-names>M. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>ЛЕОНТЬЕВА</surname><given-names>И. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Leont’ieva</surname><given-names>I. Ya.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>ШАХГИЛЬДЯН</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shakhgildyan</surname><given-names>S. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>МОРОЗОВА</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Morozova</surname><given-names>N. S.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБНУ «Научный центр неврологии», Москва<country>Россия</country></aff><aff xml:lang="en">Research Center of Neurology, Moscow<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБНУ ИПВЭ им. М. П. Чумакова, Москва&#13;
&#13;
ГБОУ ВПО РНИМУ им. Н.И. Пирогова МЗ РФ<country>Россия</country></aff><aff xml:lang="en">M. P. Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Medical Sciences, Moscow&#13;
&#13;
Department of Hospital Therapy No. 2, Faculty of Medicine, N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Moscow<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ГБУЗ ИКБ№1 ДЗМ, Москва<country>Россия</country></aff><aff xml:lang="en">Municipal Clinical Hospital No. 1, Department of Health Care, Moscow<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">ФБУЗ «Федеральный центр гигиены и эпидемиологии» Роспотребнадзора, Москва, РФ<country>Россия</country></aff><aff xml:lang="en">FBHI FCH&amp;E of the inspectorate for customers protection, Moscow, Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2015</year></pub-date><volume>14</volume><issue>3</issue><fpage>17</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; СУПОНЕВА Н.А., ШАКАРЯН А.К., РАХТЕЕНКО А.В., ПИРАДОВ М.А., МИТРОФАНОВА И.В., ПРЫТКОВА М.И., ЛЕОНТЬЕВА И.Я., ШАХГИЛЬДЯН С.В., МОРОЗОВА Н.С., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">СУПОНЕВА Н.А., ШАКАРЯН А.К., РАХТЕЕНКО А.В., ПИРАДОВ М.А., МИТРОФАНОВА И.В., ПРЫТКОВА М.И., ЛЕОНТЬЕВА И.Я., ШАХГИЛЬДЯН С.В., МОРОЗОВА Н.С.</copyright-holder><copyright-holder xml:lang="en">Suponeva N.A., Shakaryan A.K., Rakhteenko A.V., Piradov M.A., Mitrofanova I.V., Prytkova M.I., Leont’ieva I.Y., Shakhgildyan S.V., Morozova N.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://detinf.elpub.ru/jour/article/view/165">https://detinf.elpub.ru/jour/article/view/165</self-uri><abstract><p>В работе были проанализированы 42 случая острых вялых параличей (ОВП) у детей в возрасте от 7 месяцев до 15 лет, зарегистрированных в ИКБ №1 г. Москвы в период с 2007 по 2014 гг. Согласно ретроспективному анализу, ведущей причиной ОВП среди детей является Синдром Гийена-Барре (СГБ), доля которого составила 74% (31 пациент). Изучена клиническая картина и данные лабораторных и электрофизиологических исследований для выявления особенностей течения и диагностики СГБ у детей. СГБ чаще всего встречается в возрастной группе от 1 до 3 лет, медиана 6 [3;11] лет. Мальчики болеют чаще (2,1:1). Небыло выявлено сезонной зависимости СГБ: дети переносят заболевание в разные месяцы на протяжении всего года. Острая воспалительная демиелинизирующая полирадикулонейропатия (ОВДП) диагностирована у 24 детей (77%), острая моторная аксональная невропатия (ОМАН) — в 5 случаях (16%) и острая моторно-сенсорная аксональная невропатия (ОМСАН) — в 2 случаях (7%). Выявлен ряд особенностей клинической картины СГБ у детей. Ведущим симптомом в дебюте заболевания является интенсивная боль в конечностях, при этом объективные сенсорные нарушения выявляются редко (13%): в виде парестезий (10%) или гипостезий (3%). Темп нарастания параличей достаточно высокий: медиана достижения пика заболевания 9,5 [6,25; 12,5] суток от начала заболевания. На пике заболевания доля поражения ЧМН увеличивается с 23 до 51%: частота парезов VII пары возрастает с 10 до 32%, а частота бульбарного синдрома с 12 до 19% случаев. Проведено лечение внутривенным иммуноглобулином в дозе от 0,2 до 1,75 г/кг за курс (медиана 0,5 [0,5; 0,8] г/кг) и/или плазмаферезом в объёме 93 [81; 100] мл/кг за курс. В подавляющем большинстве случаев был достигнут положительный результат, но три ребёнка оказались рефрактерны к внутривенной иммунотерапии. Важной особенностью СГБ у детей является благоприятный прогноз исхода к моменту выписки из стационара, при сроках госпитализации 28 [20,5; 38] суток.</p></abstract><trans-abstract xml:lang="en"><p>A retrospective study of 42 cases of acute flaccid paralysis (AFP) in children aged between 7 months and 15 years, registered at the Municipal Clinical Hospital №1 throughout a 7 year period (2007—2014), was performed to investigate the features of pediatric Guillian-Barre Syndrome (GBS). GBS has shown to be the most common cause of AFP in children, with prevalence of 74% of all 31 cases. Clinical manifestations, functional status, laboratory and electrodiagnostic data were evaluated in group of 31 children in order to highlight particular features of childhood GBS in Russia. The highest frequency of GBS was observed in children aged between 1 to 3 with the median 6 [3; 11] years. Boys with GBS outnumbered girls by a 2,1:1 ratio. No seasonal dependence has been observed, with children equally suffering from this disease without a seasonal pattern throughout the year. According to the electrophysiological and clinical data, 24 children were diagnosed with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) (77%), 5 with acute motor axonal neuropathy (AMAN) (16%) and 2 with аcute motor-sensory axonal neuropathy (AMSAN) in a total of cases (7%). Several exclusive features of GBS in children for Russia were discovered. The most common initial symptom was limb pain, with the impartial sensory disturbance found only in 13% of the patients observed, 10% of which were paresthesias and the remaining 3% belonging to hypostesias. Children reached the nadir state rapidly, the median time from onset to nadir was 9.5 [6,25; 12,5] days. Cranial nerve dysfunction at nadir was observed in a greater percentage of patients (51%) compared to that of 23% cases at the onset, with the facial palsy increasing from 10 to 32% and the bulbar palsy from 12 to 19%. The patients were given intravenous immunoglobulin in various doses: from 0.2 to 1.75 mg/kg per course (0.5 [0.5; 0.8] g/kg) and/or plasmapheresis with a median volume of 93 [81; 100] ml/kg per course. The treatment has shown to be effective for the majority of patients, but three children was resistant to the intravenous immunoglobulin. An important feature of pediatric GBS is a nonthreatening prognosis at the point of discharge, with the length of hospitalization numbering in with a median of 28 [20,5; 38] days.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>синдром Гийена-Барре</kwd><kwd>острая воспалительная демиелинизирующая полирадикулонейропатия</kwd><kwd>острая моторная аксональная нейропатия</kwd><kwd>острая моторно-сенсорная нейропатия</kwd><kwd>эффективность терапии</kwd><kwd>восстановление</kwd><kwd>дети</kwd><kwd>педиатрия</kwd><kwd>нейропатии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Gullian-Barre syndrome</kwd><kwd>Acute flaccid paralysis</kwd><kwd>Acute inflammatory demyelinating polyradiculoneuropathy</kwd><kwd>Children</kwd><kwd>Pediatrics</kwd><kwd>Acute motor axonal neuropathy</kwd><kwd>Acute motor-sensory axonal neuropathy</kwd><kwd>Demyelinating diseases</kwd><kwd>Recovery</kwd><kwd>Effectiveness of therapy</kwd><kwd>Neuropathy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Olivé J.M., Castillo C., Castro R.G., de Quadros C.A. Epidemiologic Study of Guillain-Barré Syndrome in Children &lt; 15 Years of Age in Latin America //J Infect Dis. 1997 Feb;175 Suppl 1:S160—4.</mixed-citation><mixed-citation xml:lang="en">Olivé J.M., Castillo C., Castro R.G., de Quadros C.A. Epidemiologic Study of Guillain-Barré Syndrome in Children &lt; 15 Years of Age in Latin America //J Infect Dis. 1997 Feb;175 Suppl 1:S160—4.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Marx A., Glass J.D., Sutter R.W. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance // Epidemiol Rev 2000;22:298–316.</mixed-citation><mixed-citation xml:lang="en">Marx A., Glass J.D., Sutter R.W. Differential diagnosis of acute flaccid paralysis and its role in poliomyelitis surveillance // Epidemiol Rev 2000;22:298–316.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пирадов М.А., Супонева Н.А. Синдром Гийена-Барре: диагностика и лечение. — М.: МЕДпресс, 2011. — 208 с. Piradov M.A., Suponeva N.A. [Gullian-Barre syndrome: diagnostic and treatment]. — M., 2011. — 208 s. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Пирадов М.А., Супонева Н.А. Синдром Гийена-Барре: диагностика и лечение. — М.: МЕДпресс, 2011. — 208 с. Piradov M.A., Suponeva N.A. [Gullian-Barre syndrome: diagnostic and treatment]. — M., 2011. — 208 s. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes RA, Cornblath DR. Guillain-Barré syndrome // Lancet. 2005. Nov 5; 366(9497):1653—66.</mixed-citation><mixed-citation xml:lang="en">Hughes RA, Cornblath DR. Guillain-Barré syndrome // Lancet. 2005. Nov 5; 366(9497):1653—66.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Супонева Н.А., Мочалова Е.Г., Гришина Д.А., Пирадов М.А. Особенности течения СГБ в России: анализ 186 случаев // Нервно-мышечные болезни, 2014;1:37 — 46. Suponeva N.A., Mochalova E.G., Grishina D.A., Piradov M.A. [Some aspects of GBS in Russia: analysis of 186 cases]. — 2014;1:37 — 46. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Супонева Н.А., Мочалова Е.Г., Гришина Д.А., Пирадов М.А. Особенности течения СГБ в России: анализ 186 случаев // Нервно-мышечные болезни, 2014;1:37 — 46. Suponeva N.A., Mochalova E.G., Grishina D.A., Piradov M.A. [Some aspects of GBS in Russia: analysis of 186 cases]. — 2014;1:37 — 46. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Fokke C, Van den berg B, Drenthen J et-al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria // Brain. 2014;137 (Pt): 33—43.</mixed-citation><mixed-citation xml:lang="en">Fokke C, Van den berg B, Drenthen J et-al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria // Brain. 2014;137 (Pt): 33—43.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Супонева Н.А., Пирадов М.А.,Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к гликозидам периферических нервов при синдроме Гийена-Барре // Анн неврол 2013; 7(1):4—11.</mixed-citation><mixed-citation xml:lang="en">Супонева Н.А., Пирадов М.А.,Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к гликозидам периферических нервов при синдроме Гийена-Барре // Анн неврол 2013; 7(1):4—11.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Suponeva N.A., Piradov M.A., Nikitin S.S. et al. [Pathogenic and prognostic role of autoantibody to peripheral nerves’s glycosides]. // Ann. Nevr. 2013; 7(1):4-11.</mixed-citation><mixed-citation xml:lang="en">Suponeva N.A., Piradov M.A., Nikitin S.S. et al. [Pathogenic and prognostic role of autoantibody to peripheral nerves’s glycosides]. // Ann. Nevr. 2013; 7(1):4-11.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Van den Berg B, Walgaatd C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–482.</mixed-citation><mixed-citation xml:lang="en">Van den Berg B, Walgaatd C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469–482.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes R.A.C., Swan A.V., Raphaе? J.S. et al. Immunotherapy for Gullain-Barre syndrome: a systematic review // Brain 2007; 130:2245—57.</mixed-citation><mixed-citation xml:lang="en">Hughes R.A.C., Swan A.V., Raphaе? J.S. et al. Immunotherapy for Gullain-Barre syndrome: a systematic review // Brain 2007; 130:2245—57.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tasdemir H.A., Dilber C., Kanber Y., Uysal S. Intravenous immunoglobulin for Guillain-Barré syndrome: how effective? // J Child Neurol. 2006 Nov; 21(11):972—4.</mixed-citation><mixed-citation xml:lang="en">Tasdemir H.A., Dilber C., Kanber Y., Uysal S. Intravenous immunoglobulin for Guillain-Barré syndrome: how effective? // J Child Neurol. 2006 Nov; 21(11):972—4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Raphael J.C., Chevret S., Hughes R.A.C., Annane D. Plasma exchange for Guillain Barré syndrome // Cochrane Database of Systematic Reviews 2009, Issue 2: CD001798.</mixed-citation><mixed-citation xml:lang="en">Raphael J.C., Chevret S., Hughes R.A.C., Annane D. Plasma exchange for Guillain Barré syndrome // Cochrane Database of Systematic Reviews 2009, Issue 2: CD001798.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hadden R.D.M., Cornblath D.R., Hughes R.A.C., Zielasek J., Hartung H.P., Toyka K. et al. Electrophysiological classification of Guillain-Barré Syndrome: clinical associations and outcome // Ann Neurol, 1998; 44:780—788.</mixed-citation><mixed-citation xml:lang="en">Hadden R.D.M., Cornblath D.R., Hughes R.A.C., Zielasek J., Hartung H.P., Toyka K. et al. Electrophysiological classification of Guillain-Barré Syndrome: clinical associations and outcome // Ann Neurol, 1998; 44:780—788.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes R.A.C., Cornblath D.R. Guillain-Barré syndrome // Lancet Neurol, 2005; 366:1653—1666.</mixed-citation><mixed-citation xml:lang="en">Hughes R.A.C., Cornblath D.R. Guillain-Barré syndrome // Lancet Neurol, 2005; 366:1653—1666.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Van Doorn P.A., Kuitwaard K., Walgaard C., van Koningsveld R., Ruts L., Jacobs B.C. IVIG Treatment and Prognosis in Guillain–Barré Syndrome // Journal of Clinical Immunology. 010; 30 (Suppl 1): 74—78.</mixed-citation><mixed-citation xml:lang="en">Van Doorn P.A., Kuitwaard K., Walgaard C., van Koningsveld R., Ruts L., Jacobs B.C. IVIG Treatment and Prognosis in Guillain–Barré Syndrome // Journal of Clinical Immunology. 010; 30 (Suppl 1): 74—78.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Постановление Главного государственного санитарного врача РФ от 13.03.2013 N 11 «О Плане действий по поддержанию свободного от полиомиелита статуса Российской Федерации на 2013—2015 гг.» [Postanovlenie glavnogo sanitarnogo vracha RF]. 13.03.2013 N 11. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Постановление Главного государственного санитарного врача РФ от 13.03.2013 N 11 «О Плане действий по поддержанию свободного от полиомиелита статуса Российской Федерации на 2013—2015 гг.» [Postanovlenie glavnogo sanitarnogo vracha RF]. 13.03.2013 N 11. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barre syndrome // Ann. Neurol. 1990. V. 27. S. 21—24.</mixed-citation><mixed-citation xml:lang="en">Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barre syndrome // Ann. Neurol. 1990. V. 27. S. 21—24.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Biou D., Benoist J.F., Nguyen-Thi C., Huong X., Morel P., Marchand M. Cerebrospinal fluid protein concentrations in children: age-related values in patients without disorders of the central nervous system // Clin Chem. 2000 Mar; 46(3):399-403.</mixed-citation><mixed-citation xml:lang="en">Biou D., Benoist J.F., Nguyen-Thi C., Huong X., Morel P., Marchand M. Cerebrospinal fluid protein concentrations in children: age-related values in patients without disorders of the central nervous system // Clin Chem. 2000 Mar; 46(3):399-403.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wong M., Schlaggar B.L., Buller R.S., Storch G.A., Landt M. Cerebrospinal fluid protein concentration in pediatric patients: defining clinically relevant reference values // Arch Pediatr Adolesc Med. 2000 Aug; 154(8):827-31.</mixed-citation><mixed-citation xml:lang="en">Wong M., Schlaggar B.L., Buller R.S., Storch G.A., Landt M. Cerebrospinal fluid protein concentration in pediatric patients: defining clinically relevant reference values // Arch Pediatr Adolesc Med. 2000 Aug; 154(8):827-31.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Elovaara I., Apostolski S., van Doorn P., Gilhus N.E., Hietaharju A., Honkaniemi J., van Schaik I.N., Scolding N., Soelberg Sorensen P., Udd B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases // Eur J Neurol. 2008 Sep;15(9):893-908. Erratum in: Eur J Neurol. 2009 Apr;16(4):547.</mixed-citation><mixed-citation xml:lang="en">Elovaara I., Apostolski S., van Doorn P., Gilhus N.E., Hietaharju A., Honkaniemi J., van Schaik I.N., Scolding N., Soelberg Sorensen P., Udd B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases // Eur J Neurol. 2008 Sep;15(9):893-908. Erratum in: Eur J Neurol. 2009 Apr;16(4):547.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Korinthenberg R., Monting J.S. Natural history and treatment effects in Guillain-Barré syndrome: a multi centre study // Arch Dis Child 1996; 74:281—287.</mixed-citation><mixed-citation xml:lang="en">Korinthenberg R., Monting J.S. Natural history and treatment effects in Guillain-Barré syndrome: a multi centre study // Arch Dis Child 1996; 74:281—287.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ma Y.M., Liu T.K., Wong V. Guillain-Barre syndrome in southern Chinese children: 32 year experience in Hong Kong // Pediatr Int (2010) 52:13—19.</mixed-citation><mixed-citation xml:lang="en">Ma Y.M., Liu T.K., Wong V. Guillain-Barre syndrome in southern Chinese children: 32 year experience in Hong Kong // Pediatr Int (2010) 52:13—19.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hicks C.W., Kay B., Worley S.E., Moodley M. A clinical picture of Guillain-Barré syndrome in children in the United States // J Child Neurol. 2010 Dec; 25(12):1504—10.</mixed-citation><mixed-citation xml:lang="en">Hicks C.W., Kay B., Worley S.E., Moodley M. A clinical picture of Guillain-Barré syndrome in children in the United States // J Child Neurol. 2010 Dec; 25(12):1504—10.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ryan M.M. Guillain-Barre syndrome in childhood // J Paediatr. Child Health. 2005; 41:237—241.</mixed-citation><mixed-citation xml:lang="en">Ryan M.M. Guillain-Barre syndrome in childhood // J Paediatr. Child Health. 2005; 41:237—241.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J.H., Sung I.Y., Rew I.S. Clinical presentation and prognosis of childhood Guillain-Barre syndrome // J Paediatr Child Health. 2008; 44:449—454.</mixed-citation><mixed-citation xml:lang="en">Lee J.H., Sung I.Y., Rew I.S. Clinical presentation and prognosis of childhood Guillain-Barre syndrome // J Paediatr Child Health. 2008; 44:449—454.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome // Lancet. 1997; 349:225—230.</mixed-citation><mixed-citation xml:lang="en">Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome // Lancet. 1997; 349:225—230.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
